Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
Foundation For Technical Education populations by expanding its education model first across the East African region and then beyond. Negotiations are underway in Kenya, Zambia, Rwanda, Burundi and Uganda to work with existing technical education institutions in finding education solutions. The FTE Education Model relies on shared responsibilities based on international expertise but local ownership, entrusting the coordination and management to the local leadership team of the schools. Sharing knowledge and resources, FTE works together with like-minded organizations to develop long-term, strategic partnerships that combine targeted technical skills and a commitment to scale and replication with volunteering in education. To date, partnerships have been